Viridian Therapeutics (UK) Buy Hold or Sell Recommendation
| 0K1R Stock | 21.82 0.07 0.32% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Viridian Therapeutics is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Viridian Therapeutics given historical horizon and risk tolerance towards Viridian Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Viridian Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Viridian Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Viridian Stock please use our How to Invest in Viridian Therapeutics guide. Note, we conduct extensive research on individual companies such as Viridian and provide practical buy, sell, or hold advice based on investors' constraints. Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Viridian |
Execute Viridian Therapeutics Buy or Sell Advice
The Viridian recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Viridian Therapeutics. Macroaxis does not own or have any residual interests in Viridian Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Viridian Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Viridian Therapeutics Trading Alerts and Improvement Suggestions
| Viridian Therapeutics is way too risky over 90 days horizon | |
| Viridian Therapeutics appears to be risky and price may revert if volatility continues | |
| Viridian Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 314 K. Net Loss for the year was (237.73 M) with loss before overhead, payroll, taxes, and interest of (99.12 M). | |
| Viridian Therapeutics generates negative cash flow from operations | |
| Latest headline from news.google.com: Principal Financial Group Inc. Buys 162,665 Shares of Viridian Therapeutics, Inc. - MarketBeat |
Viridian Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Viridian analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Viridian analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Viridian Therapeutics Returns Distribution Density
The distribution of Viridian Therapeutics' historical returns is an attempt to chart the uncertainty of Viridian Therapeutics' future price movements. The chart of the probability distribution of Viridian Therapeutics daily returns describes the distribution of returns around its average expected value. We use Viridian Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Viridian Therapeutics returns is essential to provide solid investment advice for Viridian Therapeutics.
| Mean Return | 0.69 | Value At Risk | -5.11 | Potential Upside | 12.34 | Standard Deviation | 5.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Viridian Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Viridian Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (50.9M) | (57.8M) | 451K | (349K) | (314.1K) | (329.8K) | |
| Change In Cash | (7.8M) | 21.1M | (3.6M) | 113.3M | (52.8M) | (50.1M) | |
| Free Cash Flow | (36.1M) | (29.8M) | (54.9M) | (94.6M) | (185.1M) | (175.8M) | |
| Depreciation | 288K | 239K | 120K | 255K | 522K | 548.1K | |
| Other Non Cash Items | 340K | 72.6M | 7.5M | 54K | (4.7M) | (4.5M) | |
| Capital Expenditures | 84K | 42K | 338K | 797K | 898K | 942.9K | |
| Net Income | (41.9M) | (110.7M) | (79.4M) | (129.9M) | (237.7M) | (225.8M) | |
| End Period Cash Flow | 24.8M | 45.9M | 42.3M | 155.6M | 102.8M | 108.0M | |
| Investments | 28.3M | (79.8M) | (74.0M) | (114.3M) | (102.9M) | (97.8M) | |
| Change To Netincome | 3.9M | 76.0M | 22.9M | 19.8M | 22.8M | 20.3M |
Viridian Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Viridian Therapeutics or Commercial Services & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Viridian Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Viridian stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.42 | |
β | Beta against Dow Jones | 2.27 | |
σ | Overall volatility | 5.15 | |
Ir | Information ratio | 0.11 |
Viridian Therapeutics Volatility Alert
Viridian Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Viridian Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Viridian Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Viridian Therapeutics Fundamentals Vs Peers
Comparing Viridian Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Viridian Therapeutics' direct or indirect competition across all of the common fundamentals between Viridian Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Viridian Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Viridian Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Viridian Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Viridian Therapeutics to competition |
| Fundamentals | Viridian Therapeutics | Peer Average |
| Return On Equity | -0.52 | -0.31 |
| Return On Asset | -0.32 | -0.14 |
| Operating Margin | (970.70) % | (5.51) % |
| Current Valuation | 1.18 B | 16.62 B |
| Shares Outstanding | 30.84 M | 571.82 M |
| Shares Owned By Institutions | 100.00 % | 39.21 % |
| Price To Sales | 11.50 X | 11.42 X |
| Revenue | 314 K | 9.43 B |
| Gross Profit | (99.12 M) | 27.38 B |
| EBITDA | (234.56 M) | 3.9 B |
| Net Income | (237.73 M) | 570.98 M |
| Total Debt | 21.05 M | 5.32 B |
| Book Value Per Share | 6.55 X | 1.93 K |
| Cash Flow From Operations | (184.17 M) | 971.22 M |
| Earnings Per Share | (5.14) X | 3.12 X |
| Number Of Employees | 94 | 18.84 K |
| Beta | 1.11 | -0.15 |
| Market Capitalization | 2.84 T | 19.03 B |
| Total Asset | 490.42 M | 29.47 B |
| Retained Earnings | (725.91 M) | 9.33 B |
| Net Asset | 490.42 M |
Viridian Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Viridian . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Viridian Therapeutics Buy or Sell Advice
When is the right time to buy or sell Viridian Therapeutics? Buying financial instruments such as Viridian Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Viridian Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Rubber and Plastic Products Thematic Idea Now
Rubber and Plastic Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Rubber and Plastic Products theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rubber and Plastic Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.